Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma (NASDAQ: ATHA) announced a virtual R&D event titled “Enhancing the HGF/MET System to Fight Neurodegenerative Diseases,” scheduled for December 7, 2022, from 2:00 p.m. to 3:30 p.m. EST. The event will showcase preclinical and clinical data supporting the potential of HGF/MET in treating neurodegenerative diseases. Key executives, including Mark Litton, will present updates on Athira’s therapeutic pipeline, followed by an interactive Q&A session. Interested participants can pre-register and access the live webcast on Athira's website.

Athira Pharma (NASDAQ: ATHA) presented new biomarker data from the completed ACT-AD Phase 2 study of fosgonimeton, showing significant reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) that correlate with improved clinical outcomes in mild-to-moderate Alzheimer’s patients. Fosgonimeton treatment also demonstrated directional improvements in Alzheimer’s protein pathologies compared to placebo. The company continues to progress in its Phase 2/3 LIFT-AD study, aiming for topline data release in early 2024.

Athira Pharma announced positive preclinical data for its small molecule, ATH-1105, showing neuroprotective effects and improved motor and nerve function in a TDP-43 mouse model of ALS. The findings will be presented at the upcoming Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND, scheduled for December 6-9, 2022. This research highlights ATH-1105's therapeutic potential in neurodegenerative conditions, aligning with Athira's mission to restore neuronal health.

Athira Pharma, Inc. (NASDAQ: ATHA) announced promising preclinical results at Neuroscience 2022 regarding fosgonimeton, a small molecule aimed at treating Parkinson’s disease and diabetic neuropathy. The findings indicate that fosgonimeton promotes neuroprotection and enhances motor performance in Parkinson’s models. Additionally, HGF/MET modulators ATH-1018 and ATH-1020 showed significant pain reduction in diabetic neuropathy, sustaining effects even after washout periods. These developments highlight Athira's commitment to advancing treatments for neurodegeneration and pain management.

Athira Pharma (NASDAQ: ATHA) reported interim results from its LIFT-AD study, indicating potential efficacy of fosgonimeton in treating mild-to-moderate Alzheimer's disease. The independent analysis showed clinically meaningful activity without acetylcholinesterase therapy, suggesting the study can meet its primary endpoint with fewer than 150 additional patients. Financially, Athira holds $260 million in cash as of September 30, 2022, although it reported a net loss of $20.2 million for the quarter. The company anticipates completing enrollment by mid-2023 and plans to release topline data in early 2024.

Athira Pharma, Inc. (NASDAQ: ATHA), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. Management will host a fireside chat on November 16 at 4:45 p.m. EST. Interested parties can access a live webcast through the Investors section of Athira's website, with an archived replay available for 30 days post-event. Athira aims to develop small molecules for conditions like Alzheimer's and Parkinson's disease, targeting the HGF/MET neurotrophic system.

Athira Pharma announced the presentation of preclinical data on the therapeutic potential of enhancing the HGF/MET neurotrophic system for treating Parkinson’s disease and diabetic neuropathy at Neuroscience 2022. Presentations include 'Small Molecule Hepatocyte Growth Factor (HGF)/MET Positive Modulators Effectively Reduce Pain-Related Behaviors in a Rat Model of Diabetic Neuropathy' and 'Fosgonimeton Protects Against Neuronal Damage and Motor Deficits in Preclinical Models of Parkinson’s Disease'. Both presentations are scheduled for Nov. 14 and Nov. 15, 2022, respectively.

Athira Pharma announced positive interim results for its LIFT-AD study on fosgonimeton (ATH-1017) in Alzheimer’s patients. An independent committee recommended continuing the trial after finding it well powered with fewer than 300 patients enrolled and a preliminary positive effect size. The company aims to complete enrollment by mid-2023 and report topline results in early 2024. Previous Phase 2 results showed a favorable safety profile and cognitive benefits. The firm is optimistic about fosgonimeton's potential in treating Alzheimer's and plans further development.

Athira Pharma (NASDAQ: ATHA) announced updates on its LIFT-AD clinical trial of fosgonimeton, focusing on its use as monotherapy for mild-to-moderate Alzheimer's disease. Following positive results from the ACT-AD trial, the company will amend LIFT-AD to compare fosgonimeton alone against placebo, without background acetylcholinesterase inhibitors. An independent interim analysis will ensure the trial's sample size is sufficient for the primary endpoint, the Global Statistical Test. Over 90% of ACT-AD participants have opted for the ongoing open-label extension study.